<DOC>
	<DOC>NCT00332553</DOC>
	<brief_summary>This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) compared to women treated with raloxifene HCl 60 mg alone.</brief_summary>
	<brief_title>Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Post menopausal women, 5070 years of age Had taken ccHRT for at least 6 months prior to study entry No unexplained vaginal bleeding in the 3 months prior to study entry Understand and sign an informed consent document Prior hysterectomy Endometrial thickness (excluding endometrial fluid) greater than 8 mm or endometrial fluid greater than or equal to 4 mm at study entry Abnormal Pap smear at study screening or within the preceding 3 years Abnormal transvaginal ultrasound result at study screening Past or current history of malignant neoplasms</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>